COVID-19 and it’s naysayers are attacking Science and Reason. The defenders must suffer the slings and arrows from…
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
On Mar. 29, 2021, Janssen Pharmaceutica announced that it had entered into an agreement with the African Vaccine…
On Mar. 24, 2021, Virginia Tech researchers announced that their candidate Coronavirus vaccines, prevented pigs from becoming ill…
On Mar. 23, 2021, Pfizer announced that it was progressing to multiple ascending doses after completing the dosing…
On Mar. 19, 2021, scientists at the University of Oxford released pre-print data measuring the level of antibodies…
On Mar. 17, 2021, the World Health Organization (WHO) reported that the AstraZeneca COVID-19 vaccine (including Covishield) continued…
On Mar. 9, 2021, the National Institutes of Health (NIH) announced that approximately two years after establishing a…
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
On Jan. 25, 2021, the National Institutes of Health (NIH) announced that in large clinical trial conducted worldwide,…
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…
On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
On Dec. 15, 2020, Aurinia Pharmaceuticals announced the funding and initiation of an open-label exploratory trial evaluating the…
On Nov. 17, 2020, the proposed settlements between the federal government and OxyContin maker Purdue Pharma and its…
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
On Oct. 21, 2020, Purdue Pharma announced that it had entered into an agreement with the U.S. Department…
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
On Oct. 2, 2020, the World Health Organization (WHO) and the Kingdom of Saudi Arabia signed a contribution…
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…